Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Izana Bioscience tests rheumatoid arthritis drug in COVID-19 patients

Published 06/04/2020, 00:15
Updated 06/04/2020, 00:20

LONDON (Reuters) - UK-based biopharma company Izana Bioscience said it was testing its antibody therapy namilumab for the treatment of patients with rapidly worsening COVID-19 at the Humanitas Research Hospitals in Bergamo and Milan in Italy.

Namilumab is a monoclonal antibody therapy currently in late-stage clinical development for the treatment of rheumatoid arthritis and ankylosing spondylitis.

It targets a white cell growth factor called GM-CSF, which has been found in higher levels in COVID-19 patients, according to recent data from China, Izana Bioscience said. Early intervention could therefore be beneficial for patients with COVID-19, the disease caused by the new coronavirus.

Chief executive and co-founder Someit Sidhu said: "The role of GM-CSF in immune-mediated diseases is backed by a strong body of evidence and our growing understanding of COVID-19.

"Evidence suggests that anti GM-CSF therapy has the potential to change the way patients' immune systems respond to the virus, and therefore to reduce dangerous inflammation and support recovery."

The compassionate use programme is led by Professor Carlo Selmi, Izana said, while research services are being provided by Ergomed. Japan's Takeda has a strategic equity stake in Izana.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.